リファブチンによるワルファリンの代謝誘導が疑われた１例
スポンサーリンク
概要
- 論文の詳細を見る
A 40-year-old woman who had received warfarin potassium (3 mg/day) for deep-vein thrombosis was diagnosed with atypical mycobacteriosism, and concomitant administration of rifampicin, clarithromycin and ethambutol was commenced. The PT-INR of this patient, which had been maintained at around 2.0, was found to have markedly decreased 9 days after beginning co-administration of warfarin and the anti-mycobacterium drugs, suggesting rifampicin induced warfarin metabolism, which is well documented. In view of the decrease in PT-INR, the warfarin dosage was increased up to 5.5 mg/day to attain a PT-INR level in the therapeutic range, but this did not alter the level.Rifampicin was changed to rifabutin since drug-drug interaction is considered to be generally less severe than with rifampicin. However, as there had been no increase in PT-INR, the administration of rifabutin was ceased. A rise in PT-INR was observed 17 and 31 days after the withdrawal of the rifabutin and rifampicin, respectively.Warfarin is known to be metabolized by cytochrome P450 (CYP) isoforms 2C9 and 3A4 and rifampicin has been reported to be a potent inducer of CYP3A4 and 2C9. Although rifabutin has the ability to induce CYP3A4, there have been few reports of drug-drug interaction with warfarin. However, the current case provides the first evidence for rifabutin exerting an influence on warfarin metabolism.In conclusion, our findings suggest that not only rifampicin but also rifabutin induce warfarin metabolism and that its pharmacological effects could be attenuated when combined with these drugs.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)